Effectiveness of Sofosbuvir/Velpatasvir for 12 Weeks in HCV Genotype 3 Patients with Compensated Cirrhosis in Clinical Practice Cohorts from Around the World

Conference Reports for NATAP

The Liver Meeting
San Francisco
November 2018


Effectiveness of Sofosbuvir/Velpatasvir for 12 Weeks in HCV Genotype 3 Patients with Compensated Cirrhosis in Clinical Practice Cohorts from Around the World

	Reported by Jules Levin AASLD 2018 Nov 9-12 Boston